Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|October 1, 2019
Headspace platforms and services for CCI testing, oxygen monitoring, and water activity determination
Author(s)LIGHTHOUSE Instruments
LIGHTHOUSE offers solutions for Container Closure Integrity Testing, headspace Oxygen Monitoring, Moisture Determination of dry product, and Microbial Contamination inspection of media vials.
LIGHTHOUSE offers solutions for Container Closure Integrity Testing, headspace Oxygen Monitoring, Moisture Determination of dry product, and Microbial Contamination inspection of media vials. Our solutions are based on rapid non-destructive laser-based headspace analysis, a proven analytical tool for generating statistical process and product data in all stages of the product life cycle. The LIGHTHOUSE offering includes headspace analysis equipment as well as measurement services. The range of application solution activities can cover feasibility studies, analytical process and product studies, method development, method validation protocols, supply of automated or benchtop platforms, and on-site troubleshooting and support.
Contact Details
Company name: LIGHTHOUSE Instruments
Website:
E-mail:
Stand/Booth number: Hall 11, Stand 110C35
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5